MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.770
+0.040
+2.31%
After Hours: 1.770 0 0.00% 16:00 04/08 EDT
OPEN
1.750
PREV CLOSE
1.730
HIGH
1.790
LOW
1.700
VOLUME
118.98K
TURNOVER
--
52 WEEK HIGH
10.01
52 WEEK LOW
1.350
MARKET CAP
57.08M
P/E (TTM)
-1.0251
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SYBX stock price target is 7.81 with a high estimate of 13.00 and a low estimate of 2.000.

EPS

SYBX News

More
  • Edited Transcript of SYBX earnings conference call or presentation 12-Mar-20 9:00pm GMT
  • Thomson Reuters StreetEvents · 04/01 11:32
  • Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities
  • PR Newswire · 03/30 11:00
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Synlogic, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know
  • Simply Wall St. · 03/15 16:00

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About SYBX

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
More

Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.